Please ensure Javascript is enabled for purposes of website accessibility
홈 > 제품 > 항체 > 중화 항체

InVivo Plus Anti-Mouse IL-17A Antibody(BZN035) (MS856019)

InVivo Plus Anti-Mouse IL-17A Antibody(BZN035)
InVivo Plus Anti-Mouse IL-17A Antibody(BZN035)
가격(USD):
사양:
  • 1mg
  • 5mg
  • 25mg
  • 50mg
  • 100mg
수량:
문의하기
  • 개요

  • 이미지

  • 참고 문헌

  • 데이터시트

  • SDS

개요
카탈로그 번호MS856019
설명
InVivo Plus Anti-Mouse IL17A Antibody (BZN035) [BZN035] (MS856019) is a mouse monoclonal antibody detecting Interleukin-17A in FCM, Neutralization. Suitable for Mouse.
Highlights
  • ●Flow Cytometry — Validated for flow cytometry applications.
종 반응성Mouse
응용 분야FCM, Neutralization
숙주 종Mouse
클론성Monoclonal
이소타입IgG2a
클론 IDBZN035
타겟 CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A
내독소 수준 < 1 EU/mg
순도 >95% as determined by SDS-PAGE.
정제 Protein A/G purified from cell culture supernatant.
등록번호 Q62386
형태 Liquid
저장 완충액 0.01M PBS pH 7.4.

데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.

안정성 및 저장 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
배경

Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx).

_x005F_x000D_ _x005F_x000D_
1. Liang, SC. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 7791-9. PMID: 18025225
_x005F_x000D_ _x005F_x000D_
2. Ishigame, H. et al. (2009) Immunity 30, 108-19. PMID: 19144317
_x005F_x000D_ _x005F_x000D_
3. Lee, JS. et al. (2015) Immunity 43, 727-38. PMID: 26431948
_x005F_x000D_ _x005F_x000D_
4. Park, H. et al. (2005) Nature immunology 6, 1133-41. PMID: 16200068
_x005F_x000D_ _x005F_x000D_
5. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633
_x005F_x000D_ _x005F_x000D_
6. Chen, K. et al. (2016) Cell host & microbe 20, 596-605. PMID: 27923703
_x005F_x000D_
참고사항 For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Mouse IgG2a Recombinant Isotype Control Antibody (S43.10) (MF533307)
이미지
  • InVivo Plus Anti-Mouse IL-17A Antibody(BZN035)

    SDS-PAGE

    SDS-PAGE for InVivo Plus Anti-Mouse IL17A Antibody (BZN035)

참고 문헌
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
추천

문의하기 맞춤형 견적, 대량 주문 및 기타 문의 사항은

메일: [email protected]

배급사 목록